Las Vegas, USA, June 20, 2022 (GLOBE NEWSWIRE) -- Global Food Allergy Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight
Food Allergy Pipeline constitutes 35+ key companies continuously working towards developing 35+ Food Allergy treatment therapies, analyzes DelveInsight
DelveInsight’s Food Allergy Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Food Allergy pipeline domain.
Some of the essential takeaways from the Food Allergy Pipeline report:
- DelveInsight’s Food Allergy pipeline analysis depicts a robust space with 35+ active players working to develop 35+ Food Allergy pipeline treatment therapies.
- Some of the key Food Allergy companies proactively working to develop potential drug candidates to improve the Food Allergy treatment options include Merck & Co, AstraZeneca, Mabylon, GI Innovation, Aimmune Therapeutics, Inc, Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc, Vedanta Biosciences, Inc, Regeneron Pharmaceuticals, Genentech, Inc, Camallergy, Aravax, Inimmune, Prota therapeutics, Intrommune Therapeutics, Alladapt Immunotherapeutics, Siolta Therapeutics, IgGenix, Rho Federal Systems Division, Inc, and many others.
- Essential Food Allergy pipeline therapies such as Viaskin Peanut/DBV712, CA002, Omalizumab, Ligelizumab, Dupixent, Viaskin Milk, ADP101, PVX108, INT 301, PRT100, STMC-103H, AR601, and others are under development in different phases of clinical trials.
- In April 2022, Intrommune Therapeutics, announced that its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy had been amended to allow determination of the Maximum Tolerated Dose (MTD). As previously disclosed, Cohort 1 completed up-titrating to Dose 4 with no significant adverse events. Patients with peanut allergy in Cohort 2 were started at Dose 2 and are being up-titrated through 11 increasing doses of INT301 to determine both an MTD and a safe starting dose. Patients in Cohort 3 are starting at Dose 3 and participants in Cohort 4 are expected to start at Dose 4. Cohort 2 has successfully up-titrated participants through 11 doses. Cohort 3 is currently enrolling. To date, there have been no significant adverse events.
- In March 2022, Aravax, announced that it had received a green light for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA). PVX108 is a next-generation, allergen-specific immunotherapy using peptides that represent critical fragments of peanut proteins to precisely target the T cells driving peanut allergy.
- In January 2022, Alladapt Immunotherapeutics Inc., announced the completion of patient enrollment in Harmony, its Phase 1/2 study of ADP101 for the treatment of food allergy (FA).DP101, the Company’s lead program, is a potentially best-in-class oral immunotherapy (OIT) designed to desensitize patients allergic to one or multiple foods simultaneously to mitigate the risk of severe, life-threatening allergic reactions.
- In March 2021, Cambridge Allergy Ltd announced it has been awarded £1.1M funding under the Innovate UK Biomedical Catalyst Award program administered by Innovate UK, the United Kingdom’s research and innovation agency. The company planned to use the £1.1M in non-dilutive funding to accelerate the Company’s peanut allergy immunotherapy, CA002.
- Omalizumab is an investigational product, which is being developed by Genetech. Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody designed to selectively bind to human immunoglobulin E (IgE). This molecule is being developed in collaboration with Novartis. This drug is in the Phase III stage of development for the treatment of food allergy.
Request a sample and discover more about the report offerings @ Food Allergy Emerging Therapies
The Food Allergy pipeline report lays down detailed profiles of the pipeline assets, a comparative analysis of clinical and non-clinical stage Food Allergy pipeline products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Food Allergy pipeline landscape.
Food Allergy Overview
According to the National Institute of Allergy and Infectious Diseases (NIAID), a food allergy is an adverse health effect arising from a specific immune response that occurs reproducibly on exposure to a given food. Food allergens are the parts of food or ingredients within food (usual proteins) that are recognized by immune cells. When an immune cell binds to a food allergen, a reaction occurs that causes the symptoms of food allergy. “Allergy” and “allergic disease” refer to conditions that involve changes to the immune system. These immune system changes fall into two categories: Immunoglobulin E (IgE) mediated and Non-IgE-mediated.
Find out more about the disease and recent developments @ Food Allergy Pipeline Assessment
Food Allergy Pipeline Drugs
| Drug | Company | Phase | MoA | RoA |
| GI 301 | GI Innovation | Phase I | Immunoglobulin E inhibitor | Parenteral |
| INT301 | Intrommune Therapeutics | Phase I | Immunosuppressant | Transmucosal |
| ADP101 | Alladapt Immunotherapeutics | Phase I/II | Immunomodulator | Oral |
| VE416 | Vedanta Biosciences | Phase I/II | Immunomodulator | Oral |
| DBV 135 | DBV Technologies | Phase II | Immunomodulator | Epicutaneous |
| Dupilumab | Regeneron | Phase II | Interleukin 13 inhibitor | Subcutaneous |
| CA002 | Camallergy | Phase III | Immunomodulator | Oral |
| Omalizumab | Genentech | Phase III | IgE receptor antagonist | Subcutaneous |
Learn more about the novel and emerging Food Allergy pipeline therapies @ Food Allergy Pipeline Analysis
Food Allergy Pipeline Therapeutics Assessment
The Food Allergy Pipeline report proffers an integral view of the Food Allergy emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action and Route of Administration.
Scope of the Food Allergy Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Food Allergy Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Food Allergy Clinical Trial Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration, Discontinued and Inactive candidates
- Therapeutics Assessment By Food Allergy Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
- Therapeutics Assessment By Food Allergy Molecule Type: Oligonucleotide, Peptide, Small molecule
- Therapeutics Assessment By Food Allergy Mechanism of Action: Immunomodulators; Interleukin 4 inhibitors; Immunoglobulin E inhibitor; Fc gamma receptor IIB antagonist; Regulatory T-lymphocyte stimulant; Immunosuppressants; IgE receptor antagonist
- Key Food Allergy Companies: Aimmune Therapeutics, Inc, Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc, Vedanta Biosciences, Inc, Regeneron Pharmaceuticals, Genentech, Inc, Camallergy, Aravax, Inimmune, Prota therapeutics, Intrommune Therapeutics, Alladapt Immunotherapeutics, Siolta therapeutics, IgGenix and many others.
- Key Food Allergy Pipeline Therapies: Viaskin Peanut/DBV712, CA002, Omalizumab, Ligelizumab, Dupixent, Viaskin Milk, ADP101, PVX108, INT 301, PRT100, STMC-103H, AR601 and others
Dive deep into rich insights for emerging therapies and assessment, visit @ Food Allergy Pipeline and Emerging Therapies
Table of Contents
| 1 | Introduction |
| 2 | Executive Summary |
| 3 | Food Allergy: Overview |
| 4 | Pipeline Therapeutics |
| 5 | Late Stage Products (Phase III) |
| 5.1 | Omalizumab: Genentech, Inc. |
| 6 | Mid Stage Products (Phase II) |
| 6.1 | Dupilumab: Regeneron |
| 7 | Early Stage Products (Phase I/II) |
| 7.1 | INP20: InnoUp Farma |
| 8 | Preclinical and Discovery Stage Products |
| 8.1 | INI2004: Inimmune |
| 9 | Inactive Products |
| 10 | Collaborations Assessment- Licensing / Partnering / Funding |
| 11 | Food Allergy - Unmet Needs |
| 12 | Food Allergy - Market Drivers and Barriers |
| 13 | Appendix |
| 14 | About DelveInsight |
For further information on the current Food Allergy pipeline therapeutics, reach out @ Food Allergy Ongoing Clinical Trials
Related Reports
DelveInsight's "Food Allergy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Food Allergy, historical and forecasted epidemiology as well as the Food Allergy market trends, drivers and barriers, and key Foof allergy company involved like Aimmune Therapeutics, Inc., Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc., Vedanta Biosciences, Inc., Aimmune Therapeutics, Inc., Regeneron Pharmaceuticals, and many others.
DelveInsight’s ‘Food Allergy Epidemiology Forecast—2032’ report delivers an in-depth understanding of the Food Allergy (FA), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
DelveInsight’s, “Colonoscopes Pipeline Insight and Competitive Landscape, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline devices in Colonoscopes pipeline landscape like Consis Medical Inc, Cosmo Pharmaceuticals NV, Ethicon Endo-Surgery Inc, Image In, Inmotion Medical Ltd, invendo medical GmbH, Kaleidoscope, Medigus Ltd, Microbot Medical Ltd, Novadaq Technologies Inc, Olympus Corp, Omniscient LLC, and others.
DelveInsight’s ‘Hyperphosphatemia Market Insights, Epidemiology and Market Forecast– 2032’ report delivers an in-depth understanding of Hyperphosphatemia, historical and forecasted epidemiology, market drivers, market barriers, and key Hyperphosphatemia companies involved such as Akebia Therapeutics, Vifor Fresenius Medical Care Renal Pharma, Astellas Pharma, Ardelyx, Shield Therapeutics, and many others.
Diabetic Macular Edema Pipeline
DelveInsight’s, “Diabetic Macular Edema Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape such as Regeneron pharmaceuticals, RemeGen, Unity Biotechnology, KalVista Pharmaceuticals, Allergo Ophthalmics, YD Global Life Science, Aerpio Therapeutics, Ripple Therapeutics, Graybug Vision, Oxurion, Adverum Biotechnologies, Boehringer Ingelheim, Ocuphire Pharma, and others.
DelveInsight’s, “Obesity Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Obesity pipeline landscape like Eli Lilly and Company, Pfizer, Jiangsu Hansoh Pharmaceutical, MedImmune, Can-Fite Biopharma, Novo Nordisk, 10xBio, Biolingus, Shionogi, Boehringer Ingelheim, Saniona, Diasome Pharmaceuticals, and others.
DelveInsight’s ‘Acromegaly Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Acromegaly, historical and forecasted epidemiology, market drivers, market barriers, SWOT analysis, and key Acromegaly companies involved like Novartis Pharmaceuticals, Ionis Pharmaceuticals, Chiasma Pharma, Antisense Therapeutics, Camurus, GlyTech, Strongbridge Biopharma, and others.
DelveInsight’s, “Celiac Disease Pipeline Insight, 2022,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Celiac Disease pipeline landscape such as Takeda, Amgen, ImmusanT, Janssen Research & Development, LLC, Kanyos Bio, Calypso Biotech, Protagonist Therapeutics, ActoBio Therapeutics, Bioniz Therapeutics, Allero Therapeutics, and others.
DelveInsight’s ‘Ascites Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the Ascites, historical and forecasted epidemiology, market drivers, market barriers, SWOT analysis, and key Ascites companies involved such as BioVie, Noorik Biopharmaceuticals AG, and several others.
DelveInsight’s ‘Chronic pancreatitis Market Insights, Epidemiology and Market Forecast-2032' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology, market drivers, market barriers and key Chronic pancreatitis companies involved such as Aptalis Pharma, Digestive Care Inc, Kangen Pharmaceuticals, AzurRx BioPharma, and several others.
Interested to know more about the recent oncology breakthrough happenings? Take a look at the posts below
- Nutrition Intervention: Foods to take and foods to avoid when suffering from Gastroparesis
- What are the Top 9 Most Common Food Allergies and How Pharma Companies are Tackling the Crisis?
- 8 Of The Most Common Foods Allergies – Do You Have One?
- Egg Allergy Market: Second most common food allergy but no approved therapy
Other Trending Healthcare Reports
Facial Lines Market | Adult T-Cell Leukemia Market | Shingles Market | Kaposi's Sarcoma Market | Surgical Mask & Respirator Market | Stem Cell Market | Plaque Modification Devices Market | Inflammatory Pain Market | Hepatic Cirrhosis Market | Sly Syndrome Market | Shigellosis Market | Tuberculosis Market | Asperger Syndrome Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
